Sutro Biopharma Inc (STRO)

$23.78 -1.09 (-4.38%)
Market Cap 393.96M
Revenue (ttm) 102.48M
Net Income (ttm) -191.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -186.47%
Debt to Equity Ratio 0.00
Volume 126,500
Avg Vol 156,602
Day's Range N/A - N/A
Shares Out 16.57M
Stochastic %K 65%
Beta 1.31
Analysts Strong Sell
Price Target $29.00

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 881 6500
Fax: 650 553 9659
Address:
111 Oyster Point Boulevard, South San Francisco, United States
KY3000
KY3000 Apr. 2 at 7:21 PM
$STRO they got a nice war chest now, 450$ mill
0 · Reply
KY3000
KY3000 Apr. 2 at 4:19 PM
$STRO I want a reverse merger with Astellas. That will solve a lot of Astellas problems
0 · Reply
KY3000
KY3000 Mar. 30 at 8:15 PM
$STRO the float doubled. Lockup shares from Feb don’t hit market till after the 10th. I think they got another 100$MILL
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 27 at 2:20 PM
$STRO More bang for the buck in Radiopharm Theranostics Deep pipeline and $30 target at Jones
0 · Reply
KY3000
KY3000 Mar. 24 at 7:11 PM
$STRO beastmaster
0 · Reply
notreload_ai
notreload_ai Mar. 24 at 5:18 PM
$STRO ... Wall Street turns bullish on Sutro Biopharma. Wells Fargo upgrades to Overweight with $27 PT and H.C. Wainwright raises to Buy with $28 target on strong STRO-004 progress. https://notreload.xyz/wall-street-goes-bullish-on-sutro-biopharma-two-major-upgrades-after-q4-results/
0 · Reply
DARKP00L
DARKP00L Mar. 24 at 12:26 PM
$STRO 08:24 on Mar. 24 2026 Wells Fargo Upgrades Sutro Biopharma to Overweight, Raises Price Target to $27 #tradeideas
0 · Reply
Zaksab
Zaksab Mar. 24 at 12:05 PM
$STRO bravo Jane, bravo
0 · Reply
DARKP00L
DARKP00L Mar. 24 at 10:45 AM
$STRO 06:17 on Mar. 24 2026 HC Wainwright & Co. Upgrades Sutro Biopharma to Buy, Raises Price Target to $28 #tradeideas
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 24 at 1:00 AM
$STRO Q4 '25 Earnings Results & Recap Sutro Biopharma expects existing capital and February 2026 offering proceeds to fund operations for at least twelve months, with initial STRO-004 data anticipated mid-2026, and STRO-006/STRO-227 IND filings expected in 2026-2027.
0 · Reply
Latest News on STRO
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Mar 23, 2026, 4:05 PM EDT - 12 days ago

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Mar 13, 2026, 8:57 AM EDT - 23 days ago

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 5 weeks ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Feb 10, 2026, 7:00 AM EST - 7 weeks ago

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 4:46 PM EST - 2 months ago

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Nov 12, 2025, 6:22 PM EST - 5 months ago

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:30 PM EST - 5 months ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Nov 5, 2025, 4:05 PM EST - 5 months ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Nov 3, 2025, 8:00 AM EST - 5 months ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sep 29, 2025, 5:05 PM EDT - 6 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:30 PM EDT - 8 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:31 PM EDT - 11 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 15, 2025, 6:40 PM EDT - 1 year ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 14, 2025, 12:09 PM EDT - 1 year ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:05 PM EST - 1 year ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Jan 2, 2025, 6:28 PM EST - 1 year ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 13, 2024, 4:30 PM EST - 1 year ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23, 2024, 12:46 PM EDT - 1 year ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

May 13, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 5, 2024, 6:31 PM EDT - 2 years ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 6:18 AM EDT - 2 years ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Apr 2, 2024, 1:00 AM EDT - 2 years ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 25, 2024, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Jan 4, 2024, 4:05 PM EST - 2 years ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 29, 2023, 4:11 PM EST - 2 years ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Dec 14, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 11, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Dec 4, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 21, 2023, 4:05 PM EST - 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Oct 9, 2023, 9:48 AM EDT - 2 years ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sutro BioPharma: Good Stewardship Through Early Trials

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

KY3000
KY3000 Apr. 2 at 7:21 PM
$STRO they got a nice war chest now, 450$ mill
0 · Reply
KY3000
KY3000 Apr. 2 at 4:19 PM
$STRO I want a reverse merger with Astellas. That will solve a lot of Astellas problems
0 · Reply
KY3000
KY3000 Mar. 30 at 8:15 PM
$STRO the float doubled. Lockup shares from Feb don’t hit market till after the 10th. I think they got another 100$MILL
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 27 at 2:20 PM
$STRO More bang for the buck in Radiopharm Theranostics Deep pipeline and $30 target at Jones
0 · Reply
KY3000
KY3000 Mar. 24 at 7:11 PM
$STRO beastmaster
0 · Reply
notreload_ai
notreload_ai Mar. 24 at 5:18 PM
$STRO ... Wall Street turns bullish on Sutro Biopharma. Wells Fargo upgrades to Overweight with $27 PT and H.C. Wainwright raises to Buy with $28 target on strong STRO-004 progress. https://notreload.xyz/wall-street-goes-bullish-on-sutro-biopharma-two-major-upgrades-after-q4-results/
0 · Reply
DARKP00L
DARKP00L Mar. 24 at 12:26 PM
$STRO 08:24 on Mar. 24 2026 Wells Fargo Upgrades Sutro Biopharma to Overweight, Raises Price Target to $27 #tradeideas
0 · Reply
Zaksab
Zaksab Mar. 24 at 12:05 PM
$STRO bravo Jane, bravo
0 · Reply
DARKP00L
DARKP00L Mar. 24 at 10:45 AM
$STRO 06:17 on Mar. 24 2026 HC Wainwright & Co. Upgrades Sutro Biopharma to Buy, Raises Price Target to $28 #tradeideas
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 24 at 1:00 AM
$STRO Q4 '25 Earnings Results & Recap Sutro Biopharma expects existing capital and February 2026 offering proceeds to fund operations for at least twelve months, with initial STRO-004 data anticipated mid-2026, and STRO-006/STRO-227 IND filings expected in 2026-2027.
0 · Reply
KY3000
KY3000 Mar. 23 at 10:12 PM
$STRO the iadc platform works? Buy the iadc platform. 2-3 $ bill
0 · Reply
KY3000
KY3000 Mar. 23 at 10:07 PM
$STRO no one reads? 2nd target for Astellas iadc already IND enabling, triggered milestone. Evan after TD raise, 22- 23 mill shares
0 · Reply
KY3000
KY3000 Mar. 23 at 9:56 PM
$STRO astellas/Sutro at acrr at same time, lfg
0 · Reply
KY3000
KY3000 Mar. 23 at 9:55 PM
$STRO going to advance US rights for iadc/astellas. 340$ mill after TD deal. Feb offering was overprescribed is my guess
0 · Reply
KY3000
KY3000 Mar. 23 at 8:32 PM
$STRO 10k out, real bullish
0 · Reply
KY3000
KY3000 Mar. 23 at 7:22 PM
$STRO almost to dose 5 in 004. They started at the highest dose, 50mg. I’m real interested in this data
0 · Reply
betaino
betaino Mar. 23 at 5:40 PM
$STRO https://www.biospace.com/press-releases/vaxcyte-completes-enrollment-of-opus-1-and-opus-2-phase-3-trials-evaluating-vax-31-for-the-prevention-of-invasive-pneumococcal-disease-and-pneumonia-in-adults
0 · Reply
betaino
betaino Mar. 19 at 1:43 PM
$STRO https://www.biospace.com/press-releases/positive-vax-31-phase-1-2-adult-data-published-in-the-lancet-infectious-diseases-highlight-best-in-class-potential-of-vaxcytes-31-valent-pneumococcal-conjugate-vaccine-pcv-candidate
0 · Reply
KY3000
KY3000 Mar. 15 at 3:01 PM
$STRO trending for what?
0 · Reply
KY3000
KY3000 Mar. 15 at 2:08 PM
$STRO 004 schedule should of dosed level 4, level 5 is 2 weeks away. They stuck by their data as of Feb 27. Pfizer/Exelesis watching
0 · Reply
DCZ
DCZ Mar. 12 at 4:33 PM
$STRO I guess they didn’t get the memo that they were supposed to be down 5-10% today like all of my other biotech stocks. This stock is really strong. Somebody knows something and is buying up everything.
1 · Reply
KY3000
KY3000 Mar. 12 at 4:04 PM
$STRO this is acting like it wants 50$
0 · Reply